{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T06:04:25Z","timestamp":1770530665913,"version":"3.49.0"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI14C1277"],"award-info":[{"award-number":["HI14C1277"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>In the backdrop of rapidly changing relapsed\/refractory (RR) multiple myeloma (MM) treatment schema that mainly evolves around immunotherapies, it is easy to disregard more traditional drugs. Finding the best partner for pomalidomide, a potent third-generation immunomodulatory drug, is an important agenda we face as a community and cyclophosphamide addition has been used for outcomes augmentation. We carried out this real-world study to identify patients who will show durable response to pomalidomide and those who will benefit from cyclophosphamide addition. A total of 103 patients (57 in pomalidomide-dexamethasone [Pd] group versus 46 in pomalidomide-cyclophosphamide-dexamethasone [PCd]) were studied. They were previously treated with bortezomib (98.1%) or lenalidomide (100%) and previous lines of therapy were median 3 lines. Significantly better overall response rate (ORR) was seen in the PCd (75.6%) than Pd (41.7%) group (<jats:italic>p<\/jats:italic> = 0.001), but no differences in survival outcomes. Subgroup analysis revealed that high-risk myeloma features, poor response to lenalidomide or bortezomib had superior ORRs when cyclophosphamide was added. Also, long-term responders for pomalidomide were associated with excellent response to previous IMiD treatments. Pomalidomide-based therapy was discontinued in five patients due to intolerance or adverse events, but there was no mortality during treatment. In conclusion, we showed that pomalidomide-based treatment is still relevant and can ensure durable response in RRMM setting, especially for patients who responded well to previous lenalidomide. Addition of cyclophosphamide to Pd is associated with better ORR, and can be positively considered in fit patients with high-risk MM, extramedullary disease, and less-than-satisfactory response to previous lenalidomide treatment.<\/jats:p>","DOI":"10.1371\/journal.pone.0260113","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T18:27:10Z","timestamp":1643308030000},"page":"e0260113","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cyclophosphamide addition to pomalidomide\/dexamethasone is not necessarily associated with universal benefits in RRMM"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5646-8054","authenticated-orcid":true,"given":"Hyunkyung","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1780-5553","authenticated-orcid":true,"given":"Ja Min","family":"Byun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2591-7459","authenticated-orcid":true,"given":"Sung-Soo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youngil","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sock-Won","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Yeop","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junshik","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"issue":"3","key":"pone.0260113.ref001","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2015.223","article-title":"Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives","volume":"30","author":"S Lonial","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"pone.0260113.ref002","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"B Yu","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"4","key":"pone.0260113.ref003","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"N Shah","year":"2020","journal-title":"Leukemia"},{"issue":"2","key":"pone.0260113.ref004","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.24954","article-title":"Efficacy of VDT PACE-like regimens in treatment of relapsed\/refractory multiple myeloma","volume":"93","author":"A Lakshman","year":"2018","journal-title":"Am J Hematol"},{"issue":"10","key":"pone.0260113.ref005","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-019-0245-1","article-title":"Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed\/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network","volume":"9","author":"CY Soekojo","year":"2019","journal-title":"Blood cancer journal"},{"issue":"21","key":"pone.0260113.ref006","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2015-11-682518","article-title":"Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma","volume":"127","author":"RC Baz","year":"2016","journal-title":"Blood"},{"issue":"24","key":"pone.0260113.ref007","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1182\/blood-2018-07-863829","article-title":"Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma","volume":"132","author":"L Garderet","year":"2018","journal-title":"Blood"},{"issue":"6","key":"pone.0260113.ref008","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00277-019-03649-3","article-title":"Pomalidomide, cyclophosphamide, and dexamethasone for relapsed\/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study","volume":"98","author":"S Trudel","year":"2019","journal-title":"Annals of hematology"},{"issue":"1","key":"pone.0260113.ref009","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00277-013-1952-5","article-title":"DCEP for relapsed or refractory multiple myeloma after therapy with novel agents","volume":"93","author":"S Park","year":"2014","journal-title":"Ann Hematol"},{"issue":"1","key":"pone.0260113.ref010","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"H Quach","year":"2010","journal-title":"Leukemia"},{"key":"pone.0260113.ref011","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1038\/bcj.2013.38","article-title":"Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma","volume":"3","author":"AA Chanan-Khan","year":"2013","journal-title":"Blood Cancer J"},{"issue":"15","key":"pone.0260113.ref012","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1158\/1078-0432.CCR-09-0344","article-title":"Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy","volume":"15","author":"PH O\u2019Donnell","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"5","key":"pone.0260113.ref013","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/bjh.14465","article-title":"Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial","volume":"176","author":"J Lu","year":"2017","journal-title":"British journal of haematology"},{"issue":"2","key":"pone.0260113.ref014","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/19371910903070333","article-title":"Introduction: health of the health care system in Korea","volume":"25","author":"DS Kim","year":"2010","journal-title":"Soc Work Public Health"},{"key":"pone.0260113.ref015","unstructured":"Network NCC. Antiemesis. 2021."},{"issue":"18","key":"pone.0260113.ref016","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"SV Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"suppl_4","key":"pone.0260113.ref017","doi-asserted-by":"crossref","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"P Moreau","year":"2017","journal-title":"Annals of oncology: official journal of the European Society for Medical Oncology"},{"issue":"13","key":"pone.0260113.ref018","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1182\/blood-2015-06-653261","article-title":"How I treat high-risk myeloma","volume":"126","author":"S Lonial","year":"2015","journal-title":"Blood"},{"issue":"6","key":"pone.0260113.ref019","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/bjh.14547","article-title":"Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience","volume":"176","author":"N Maciocia","year":"2017","journal-title":"British journal of haematology"},{"issue":"11","key":"pone.0260113.ref020","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"JS Miguel","year":"2013","journal-title":"The Lancet Oncology"},{"issue":"4","key":"pone.0260113.ref021","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2016-02-700872","article-title":"Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma","volume":"128","author":"MA Dimopoulos","year":"2016","journal-title":"Blood"},{"issue":"20","key":"pone.0260113.ref022","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1200\/JCO.2017.76.1742","article-title":"Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed\/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial","volume":"36","author":"M Dimopoulos","year":"2018","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"issue":"2","key":"pone.0260113.ref023","first-page":"e528","article-title":"Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up","volume":"5","author":"MA Dimopoulos","year":"2021","journal-title":"Hemasphere"},{"issue":"2","key":"pone.0260113.ref024","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","article-title":"CAR T cell therapies for patients with multiple myeloma","volume":"18","author":"L Mikkilineni","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"23","key":"pone.0260113.ref025","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/bloodadvances.2019000539","article-title":"Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide\/dexamethasone","volume":"3","author":"E Kastritis","year":"2019","journal-title":"Blood advances"},{"issue":"2","key":"pone.0260113.ref026","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/cancers12020407","article-title":"Multiple Myeloma: Available Therapies and Causes of Drug Resistance","volume":"12","author":"V Pinto","year":"2020","journal-title":"Cancers (Basel)"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0260113","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T18:27:37Z","timestamp":1643308057000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0260113"}},"subtitle":[],"editor":[{"given":"David","family":"Dingli","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0260113","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,27]]}}}